City Hill Ventures

City Hill Ventures

City Hill Ventures

Please visit @JLimMD Twitter handle
Follow us
$36,000,000 Venture capital (Series B)
FinSMEs , Pulse 2.0

Erasca Completes $36M Extension of Series B Financing

Xconomy

Bio Roundup: Remdesivir Data, Erasca’s $200M, a New FDA Nod & More

$200,000,000 Venture capital (Series B)
thetechstartups , Pulse 2.0

Biotech startup Erasca raises $200 million Series B funding to fight cancer

DealStreetAsia , Crunchbase News , FinSMEs , +1

Singapore’s EDBI joins US oncology startup Erasca’s $200m Series B round

$22,000,000 Venture capital (Series A)
FinSMEs

Erasca Raises Series A Extension; Round Totals $64M

$42,000,000 Venture capital (Series A)
StartupWorld

Erasca Launches With $42 Million To Support Erasing Cancer

Xconomy

Another Precision Step for Roche as Ignyta Drug Heads to Regulators

AVCJ

China's HighLight to exit US-based biotech player Bonti

$15,500,000 Venture capital (Series C)
VentureWire , PE HUB

Former Botox Bosses Raise $15.5 Million for Biotech Startup Bonti

FinSMEs

Bonti Closes $15.5M Series C Funding

Funding Health
MedCity News

Roche's $1.7B precision medicine acquisition of Ignyta targets cancers with rare mutations

Health Strategy
Bloomberg

Roche to Buy U.S. Cancer-Drug Maker Ignyta for $1.7 Billion

Health Strategy
$11,700,000 Venture capital (Series B)
businesswire

Bonti Raises $11.7 Million in an Oversubscribed Series B Financing to Advance Development of Lead Product EB-001

Xconomy

In Turnaround Saga, Ignyta Nears Crucial Phase in Cancer Drug Trial

Health Science
$42,000,000 Post-IPO debt
businesswire

Ignyta Secures $42 Million Term Loan Facility | Business Wire